Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. NVDA
9. BLZE
10. NKE

Go back to Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

Alnylam Pharma (ALNY) Tops Q1 EPS by 62c, Beats on Revenue; Offers FY23 Guidance

May 4, 2023 8:06 AM EDT

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.06), $0.62 better than the analyst estimate of ($1.68). Revenue for the quarter came in at $319.29 million versus the consensus estimate of $312.27 million.

For FY23 the company guided:

Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO: $1,200 million... More